North America Prostate Cancer Nuclear Medicine Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Type (PET and SPECT), PET Product (F-18, C-11, and Ga68-PSMA), and End User (Hospitals, Clinics, and Others)
The North America prostate cancer nuclear medicine market is expected to grow from US$ 258.86 million in 2022 to US$ 474.22 million by 2028; it is estimated to grow at a CAGR of 10.6% from 2022 to 2028..
The rise in PSA levels increases the risk of prostate cancer. PSA levels in the blood are measured in nanograms per milliliter (ng/mL) units. There is no definitive cutoff point that can determine if a man has prostate cancer or not. When assessing whether a man needs further testing, many doctors choose a PSA cutoff of 4 ng/mL or above, while others may advocate starting at a lower level, such as 2.5 or 3. Therefore, testing PSA levels in a man's blood can detect prostate cancer early. Also, a digital rectal exam (DRE) is another approach to detecting prostate cancer. The doctor uses a gloved, lubricated finger to feel the prostate gland during the exam. Regular screening with a well-validated biomarker could lead to quicker detection of localized disease. Furthermore, distinguishing between low-grade and high-grade disease is critical to avoid unnecessary biopsies, undertreatment of serious disease, and overtreatment of indolent disease.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the North America prostate cancer nuclear medicine market. The North America prostate cancer nuclear medicine market is expected to grow at a good CAGR during the forecast period.
North America Prostate cancer nuclear medicine Market Revenue and Forecast to 2028 (US$ Million)
North America Prostate cancer nuclear medicine Market Segmentation
The North America prostate cancer nuclear medicine market is segmented into type, PET product, end user, and country. Based on type, the North America prostate cancer nuclear medicine market is divided into PET and SPECT. The PET dominated the North America prostate cancer nuclear medicine market in 2022. Based on PET product, the North America prostate cancer nuclear medicine market is categorized into F-18, C-11, and Ga68-PSMA. The F-18 segment dominated the North America prostate cancer nuclear medicine market in 2022. Based on end user, the North America prostate cancer nuclear medicine market is categorized into hospitals, clinics, and others. The hospitals segment dominated the North America prostate cancer nuclear medicine market in 2022. Based on country, the North America prostate cancer nuclear medicine market is segmented into the US, Canada, and Mexico. The US segment dominated the North America prostate cancer nuclear medicine market in 2022.
Blue Earth Diagnostics Limited; ImaginAb; Curium; Jubilant Radiopharma; NCM-USA LLC; ABX advanced biochemical compounds GmbH; Telix Pharmaceuticals Ltd; Novartis AG; Theragnostics; and Lantheus Medical Imaging, Inc. by Altair are among the leading companies in the North America prostate cancer nuclear medicine market.
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 North America Prostate Cancer Nuclear Medicine Diagnostics Market – By Type
1.3.2 North America Prostate Cancer Nuclear Medicine Diagnostics Market – By PET Product
1.3.3 North America Prostate Cancer Nuclear Medicine Diagnostics Market – By End User
1.3.4 North America Prostate Cancer Nuclear Medicine Diagnostics Market – By Country
2. Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Prostate Cancer Nuclear Medicine Diagnostics Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America PEST Analysis
4.3 Experts Opinion
5. North America Prostate Cancer Nuclear Medicine Diagnostics Market– Key Market Dynamics
5.1 Market Drivers
5.1.1 Rising Prevalence of Prostate Cancer
5.1.2 Surging Demand for Early and Precise Diagnosis of Prostate Cancer
5.2 Market Restraints
5.2.1 High Cost Related to the Prostate Cancer Diagnostics and Treatment
5.3 Market Opportunities
5.3.1 Growing Use of Radiopharmaceuticals in Prostate Cancer
5.4 Future Trends
5.4.1 Increasing Research Activities for Development of Innovative Imaging Agents
5.5 Impact Analysis
6. Prostate Cancer Nuclear Medicine Diagnostics Market– North America Analysis
6.1 North America Prostate Cancer Nuclear Medicine Diagnostics Market Revenue Forecast and Analysis
7. North America Prostate Cancer Nuclear Medicine Diagnostics Market Analysis – By Type
7.1 Overview
7.2 North America Prostate Cancer Nuclear Medicine Diagnostics Market, By Type, 2022 & 2028 (%)
7.3 SPECT
7.3.1 Overview
7.3.2 SPECT: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts to 2028 (US$ Million)
7.4 PET
7.4.1 Overview
7.4.2 PET: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts to 2028 (US$ Million)
8. North America Prostate Cancer Nuclear Medicine Diagnostics Market Analysis – By PET Product
8.1 Overview
8.2 North America Prostate Cancer Nuclear Medicine Diagnostics Market, By PET Product, 2022 & 2028 (%)
8.3 F-18
8.3.1 Overview
8.3.2 F-18: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecast to 2028 (US$ Million)
8.4 C-11
8.4.1 Overview
8.4.2 C-11: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecast to 2028 (US$ Million)
8.5 GA 68 PSMA
8.5.1 Overview
8.5.2 GA 68 PSMA: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecast to 2028 (US$ Million)
9. North America Prostate Cancer Nuclear Medicine Diagnostics Market – By End User
9.1 Overview
9.2 North America Prostate Cancer Nuclear Medicine Diagnostics Market Share by End User- 2022 & 2028 (%)
9.3 Hospitals
9.3.1 Overview
9.3.2 Hospitals: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecast to 2028 (US$ Million)
9.4 Clinics
9.4.1 Overview
9.4.2 Clinics: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecast to 2028 (US$ Million)
9.5 Others
9.5.1 Overview
9.5.2 Others: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecast to 2028 (US$ Million)
10. North America Prostate Cancer Nuclear Medicine Diagnostics Market – By Country Analysis
10.1 North America: Prostate Cancer Nuclear Medicine Diagnostics Market
10.1.1 Overview
10.1.2 North America: Prostate Cancer Nuclear Medicine Diagnostics Market, by Country, 2022 & 2028 (%)
10.1.2.1 US: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
10.1.2.1.1 Overview
10.1.2.1.2 US: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
10.1.2.1.3 US: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type, 2019–2028 (US$ ‘Million)
10.1.2.1.4 US: Prostate Cancer Nuclear Medicine Diagnostics Market, PET Product, 2019–2028 (US$ ‘Million)
10.1.2.1.5 US: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User, 2019–2028 (US$ ‘Million)
10.1.2.2 Canada: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
10.1.2.2.1 Overview
10.1.2.2.2 Canada: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
10.1.2.2.3 Canada: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type, 2019–2028 (US$ ‘Million)
10.1.2.2.4 Canada: Prostate Cancer Nuclear Medicine Diagnostics Market, PET Product, 2019–2028 (US$ ‘Million)
10.1.2.2.5 Canada: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User, 2019–2028 (US$ ‘Million)
10.1.2.3 Mexico: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
10.1.2.3.1 Overview
10.1.2.3.2 Mexico: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
10.1.2.3.3 Mexico: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type, 2019–2028 (US$ ‘Million)
10.1.2.3.4 Mexico: Prostate Cancer Nuclear Medicine Diagnostics Market, PET Product, 2019–2028 (US$ ‘Million)
10.1.2.3.5 Mexico: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User, 2019–2028 (US$ ‘Million)
11. Prostate Cancer Nuclear Medicine Diagnostics Market–Industry Landscape
11.1 Overview
11.2 Growth Strategies in the Prostate Cancer Nuclear Medicine Diagnostics Market, 2021-2028
11.3 Inorganic Growth Strategies
11.3.1 Overview
11.4 Organic Growth Strategies
11.4.1 Overview
12. Company Profiles
12.1 Blue Earth Diagnostics Limited
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 ImaginAb
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Curium
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Jubilant Radiopharma
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 NCM-USA LLC
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 ABX advanced biochemical compounds GmbH
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Telix Pharmaceuticals Ltd.
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 Novartis AG
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 Theragnostics
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
12.10 Lantheus Medical Imaging, Inc.
12.10.1 Key Facts
12.10.2 Business Description
12.10.3 Products and Services
12.10.4 Financial Overview
12.10.5 SWOT Analysis
12.10.6 Key Developments
13. Appendix
13.1 About The Insight Partners
13.2 Glossary of Terms
LIST OF TABLES
Table 1. US: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ ‘Million)
Table 2. US: Prostate Cancer Nuclear Medicine Diagnostics Market, PET Product – Revenue and Forecast to 2028 (US$ ‘Million)
Table 3. US: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ ‘Million)
Table 4. Canada: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ ‘Million)
Table 5. Canada: Prostate Cancer Nuclear Medicine Diagnostics Market, PET Product – Revenue and Forecast to 2028 (US$ ‘Million)
Table 6. Canada: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ ‘Million)
Table 7. Mexico: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ ‘Million)
Table 8. Mexico: Prostate Cancer Nuclear Medicine Diagnostics Market, PET Product – Revenue and Forecast to 2028 (US$ ‘Million)
Table 9. Mexico: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ ‘Million)
Table 10. Recent Inorganic Growth Strategies in the Prostate Cancer Nuclear Medicine Diagnostics Market
Table 11. Recent Organic Growth Strategies in the Prostate Cancer Nuclear Medicine Diagnostics Market
Table 12. Glossary of Terms, Prostate Cancer Nuclear Medicine Diagnostics Market
LIST OF FIGURES
Figure 1. North America Prostate Cancer Nuclear Medicine Diagnostics Market Segmentation
Figure 2. North America Prostate Cancer Nuclear Medicine Diagnostics Market, By Country
Figure 3. North America Prostate Cancer Nuclear Medicine Diagnostics Market Overview
Figure 4. PET Segment Held Largest Share of Type Segment in Prostate Cancer Nuclear Medicine Diagnostics Market
Figure 5. US is Expected to Show Remarkable Growth During the Forecast Period
Figure 6. North America: PEST Analysis
Figure 7. North America Experts Opinion
Figure 8. North America Prostate Cancer Nuclear Medicine Diagnostics Market Impact Analysis of Drivers and Restraints
Figure 9. North America Prostate Cancer Nuclear Medicine Diagnostics Market– Revenue Forecast and Analysis – 2022 - 2028
Figure 10. North America Prostate Cancer Nuclear Medicine Diagnostics Market, by Type, 2022 & 2028 (%)
Figure 11. North America SPECT: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts to 2028 (US$ Million)
Figure 12. North America PET: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts to 2028 (US$ Million)
Figure 13. North America Prostate Cancer Nuclear Medicine Diagnostics Market, by PET Product, 2022 & 2028 (%)
Figure 14. North America F-18: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts To 2028 (US$ Million)
Figure 15. North America C-11: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts To 2028 (US$ Million)
Figure 16. North America GA 68 PSMA: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts To 2028 (US$ Million)
Figure 17. North America Prostate Cancer Nuclear Medicine Diagnostics Market Share by End User - 2022 & 2028 (%)
Figure 18. North America Hospitals: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts To 2028 (US$ Million)
Figure 19. North America Clinics: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts To 2028 (US$ Million)
Figure 20. North America Others: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts To 2028 (US$ Million)
Figure 21. North America: Prostate Cancer Nuclear Medicine Diagnostics Market, by Key Country – Revenue (2022) (US$ ‘Million)
Figure 22. North America: Prostate Cancer Nuclear Medicine Diagnostics Market, by Country, 2022 & 2028 (%)
Figure 23. US: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
Figure 24. Canada: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
Figure 25. Mexico: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
Figure 26. Growth Strategies in the Prostate Cancer Nuclear Medicine Diagnostics Market, 2021-2028
- Blue Earth Diagnostics Limited
- ImaginAb
- Curium
- Jubilant Radiopharma
- NCM-USA LLC
- ABX advanced biochemical compounds GmbH
- Telix Pharmaceuticals Ltd
- Novartis AG
- Theragnostics
- Lantheus Medical Imaging, Inc.
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America prostate cancer nuclear medicine market.
- Highlights key business priorities in order to assist companies to realign their business strategies
- The key findings and recommendations highlight crucial progressive industry trends in the North America prostate cancer nuclear medicine market, thereby allowing players across the value chain to develop effective long-term strategies
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
- Scrutinize in-depth North America market trends and outlook coupled with the factors driving the North America prostate cancer nuclear medicine market, as well as those hindering it
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution